Evaluating progression and quality of life in patients with age-related macular degeneration

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The VERA-AMD study is a prospective, observational study that aims to evaluate the clinical progression, prognostic factors, and quality of life in patients aged 50 and older with age-related macular degeneration (AMD). By analyzing real-world clinical data from 200 patients, the study seeks to identify key predictors of disease progression and functional outcomes. Primary outcomes include the rate of progression to advanced AMD and changes in visual acuity, while secondary outcomes focus on retinal morphology and quality of life assessments. The study integrates anti-VEGF therapy and AI-based fluid analysis to explore their impact on disease management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age ≥ 50 years.
* confirmed diagnosis of AMD in at least one eye.
* follow-up scheduled according to standard clinical practice.

Exclusion Criteria:

* presence of other significant ocular conditions that could affect visual acuity.
* systemic conditions that make the patient unsuitable for long-term follow-up.

Where it's running

• Department of Ophthalmology
  Udine, Ud, Italy Recruiting

Study contacts

• Principal investigator: Daniele Veritti — Department of Ophthalmology, University of Udine
• Study coordinator: Daniele Veritti
• Email: daniele.veritti@uniud.it
• Phone: +390432559907

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding Age-Related Macular Degeneration and Its Progression

  This study looks at how age-related macular degeneration develops and progresses by comparing people with the condition to healthy individuals, using non-invasive tests and personal feedback.

  Recruiting Center for Eye Research Australia · East Melbourne, Victoria · NCT04739319

• Blepharoptosis After Repeated Anti-VEGF Injections in One Eye

  This study tests whether repeated intravitreal anti-VEGF injections in one eye affect eyelid position compared with the untreated fellow eye.

  Recruiting Fatih Sultan Mehmet Training and Research Hospital · Istanbul · NCT07821450

• First-in-human test of ARO-033 in adults

  This study tests whether ARO-033 is safe and tolerable, and how it behaves in the body, in healthy adults and in adults with age-related macular degeneration.

  Recruiting Phase 1 Arrowhead Pharmaceuticals · Auckland · NCT07662096

• Predicting Risk of AMD Progression Using Imaging in Aging Eyes

  Researchers are test a new screening approach to detect early AMD and monitor its progression in adults 55 and older, to see if personalized monitoring can help in community settings.

  Recruiting at 2 sites Singapore National Eye Centre · Singapore and 1 other locations · NCT07653269

• C.001 for retinal degeneration: a first-in-human dose-escalation safety test

  A first-in-human study will test the safety and tolerability of a single subretinal injection of C.001 in adults with retinal diseases involving retinal pigment epithelium degeneration.

  Recruiting at 2 sites Phase 1 Cellio Therapeutics Inc · Beverly Hills, California and 2 other locations · NCT07594236

• Central microperimetry and radial OCT in geographic atrophy

  We will test whether central microperimetry and radial OCT scans can more accurately measure how geographic atrophy progresses toward the fovea in people with or at risk for GA from age-related macular degeneration.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07556406

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.